Urolithin A for Muscle Mass Maintenance

Reviewed by SOMA HEALTH's Medical Research Team

Muscle is not just about strength or looks. It is metabolically active tissue that stabilizes joints, stores nutrients, and helps you stay independent as you age. After 40, and especially during rapid weight loss, holding onto that tissue takes intention. Here is how the mitochondrial biology of muscle works, and where the human evidence on urolithin A actually stands.

Why muscle mass gets harder to keep after 40

From roughly the fourth decade of life, most adults lose lean muscle at a slow, steady pace unless they actively work against it. Researchers call the age-related version of this loss sarcopenia. It is driven by several overlapping changes: fewer and less responsive muscle stem cells, a blunted ability to build new muscle protein after meals and exercise (sometimes called anabolic resistance), reduced physical activity, and a decline in the health of the mitochondria that power muscle fibers.

That last point matters more than people expect. Skeletal muscle is one of the most mitochondria-dense tissues in the body, because contraction is energy-hungry. When the mitochondrial network inside a muscle fiber becomes crowded with damaged, inefficient units, the fiber produces less usable energy and generates more metabolic byproducts. Keeping that network clean and functional is a genuine part of the muscle-maintenance picture, alongside the two levers with the strongest evidence of all: resistance training and adequate protein.

The GLP-1 era: fast weight loss, and a lean-mass question

GLP-1-based medications have made substantial, rapid weight loss achievable for many people. But a recurring theme in the clinical literature is that when weight comes off quickly, a meaningful share of what is lost can be lean tissue, not only fat. Reviews of GLP-1 therapies note that lean-mass loss is common during rapid weight reduction and that strategies to protect muscle, mainly resistance exercise and sufficient protein intake, are important companions to treatment.

To be clear about scope: urolithin A is not a weight-loss aid, not a substitute for any medication, and not a treatment for any condition. If you are taking a GLP-1 medication or considering one, that is a conversation for you and your prescribing clinician, who can help you build a muscle-protective plan. What a mitochondrial-support ingredient may offer is a complementary angle on cellular quality, not a replacement for the fundamentals.

What urolithin A is, and why it is studied for muscle

Urolithin A (UA) is a gut postbiotic. It is not found in meaningful amounts in food directly; instead, your gut microbiome makes it from ellagitannins, compounds concentrated in pomegranates, walnuts, and certain berries. Importantly, only some people carry the microbial species needed to convert those precursors efficiently, which is one reason direct supplementation has been investigated.

The mechanism that drew researchers to muscle is mitophagy, the cell's process for identifying worn-out mitochondria and recycling them so healthier ones can take their place. Because muscle depends so heavily on mitochondrial output, an ingredient that supports this quality-control process is a plausible candidate for muscle research. Plausible is the operative word: mechanism explains why a hypothesis is worth testing, not whether it works in people.

The strongest human evidence: strength and endurance

Two randomized human trials anchor the muscle story. In a 2022 randomized controlled trial in middle-aged adults published in Cell Reports Medicine (Singh et al.), four months of urolithin A at 500 mg and 1,000 mg per day was associated with improvements in measures of muscle strength and aspects of exercise performance versus placebo. Separately, a 2022 randomized trial in older adults in JAMA Network Open (Liu, D'Amico et al.) reported improvements in muscle endurance over roughly four months. These are human, placebo-controlled findings, and they are the reason UA is discussed in a muscle context at all.

Underpinning both is the first-in-human work by Andreux and colleagues, published in Nature Metabolism in 2019. That study established that urolithin A was safe and well tolerated at single doses up to 1,000 mg per day and produced a mitochondrial gene-expression signature in muscle consistent with the proposed mechanism. Safety and a plausible biological footprint are meaningful, but on their own they are a starting line, not a finish.

Newer human research: trained and athletic populations

More recent trials have extended the work into people who already train. An 8-week randomized controlled trial in resistance-trained men, published in the Journal of the International Society of Sports Nutrition in 2024, examined urolithin A alongside a structured training program. A 2025 trial in distance runners has also added to the athletic-population data. These newer studies are encouraging and broaden the range of people studied, but they remain relatively short and modest in size. They are best read as building on, not yet confirming beyond doubt, the earlier findings.

A related 2025 randomized controlled trial in Nature Aging reported that about 28 days of urolithin A supported the mitochondrial health of immune cells in midlife adults, in the context of age-related low-grade inflammation. That is a different tissue than muscle, but it reinforces a consistent theme across the human literature: the signal that keeps appearing is mitochondrial support.

Preclinical origins (label: animal and cell research)

The foundational discovery came from preclinical work. Ryu and colleagues, publishing in Nature Medicine in 2016, showed that urolithin A induced mitophagy, extended lifespan in the worm C. elegans, and improved measures of muscle function in rodents. This research is why the ingredient exists as a supplement, but it is animal and cell-based. Effects seen in worms and mice do not automatically translate to humans, which is exactly why the later human trials matter so much.

An honest summary of the field, echoed by a 2024 systematic review in Ageing Research Reviews, is that the human evidence for urolithin A is still emerging: promising, consistent around a mitochondrial mechanism, but not yet extensive or long-term.

Where UA fits in a practical muscle-maintenance plan

No supplement outranks the basics, and urolithin A does not change that order.

• Resistance training first. Progressive strength work is the single most reliable stimulus for keeping muscle, at any age and during weight loss.
• Protein sufficiency. Spreading adequate protein across the day supports the muscle-building response to training.
• Consistency over intensity. A sustainable routine beats an aggressive one you abandon.
• Mitochondrial support as a complement. This is where an ingredient like urolithin A may play a supporting role, on top of the fundamentals rather than instead of them.

For the studied dose and how it is used, see our urolithin A dosage guide, and for a plain-language overview of the ingredient, our complete urolithin A guide. If you are comparing products, our roundup of the best urolithin A gummies explains what to look for on a label, and our page on urolithin A for muscle goes deeper on the training-adjacent evidence.

A note on scope: muscle loss can be a sign of an underlying medical issue, and rapid weight loss carries its own considerations. Urolithin A is not a treatment for sarcopenia, frailty, or any condition, and it is not a substitute for medical care. If you are concerned about muscle loss, are on a GLP-1 medication, or have a health condition, please talk with your doctor.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.